COVID-19: Licensing agreement for new candidate drug ‘an important first step’
Access to a new COVID-19 drug will be expanded in low- and middle-income countries following a voluntary licensing agreement between the pharmaceutical company Pfizer and a UN-backed global health initiative announced in Geneva on Tuesday. The oral antiviral therapy PF-07321332 is designed to block the activity